Inclusion Criteria:

- Histological confirmation of adenocarcinoma/squamous cell carcinoma of the
esophagus. Patients should be considered resection candidates, Clinical Stages II-
IV (For GE junction tumors 50% of the tumor must be within the esophagus)

- Age 19 years

- Male or female gender (not pregnant or lactating). If the subject is fertile, use of
medically acceptable contraception will be required, and women with reproductive
potential shall have a negative pregnancy test.

- Patient should be able to understand and offer signed written informed consent prior
to study entry.

- No prior receipt of surgery, chemotherapy, radiotherapy or immunotherapy.

- Patients must demonstrate a ECOG P.S. ≤ 1

- Minimum life expectancy of 12 weeks

- End Organ function must be adequate meeting the below criteria at baseline:

WBC 3000/mm3, ANC 1500/mm3 , Hgb 9.0 g/dL, PLT 100,000mm3 Normal serum creatinine (
1.5 mg/dL) Total Bilirubin ULN, Transaminases (SGOT and/or SGPT) may be up to 1.5 x
institutional upper limit of normal (ULN) if alkaline phosphatase is < ULN, or alkaline
phosphatase may be up to 4 x ULN if transaminases are < ULN.

PT/PTT below the upper limit of normal (patients may be on 1mg of Coumadin for line
patency) Peripheral neuropathy must be < Grade 1

Exclusion Criteria:

- Diagnosis of active, invasive (treated in past 5 years) concomitant malignancy except
non-melanotic skin cancer

- Patients must be fully recovered from any reversible side effects of prior
intervention

- Presence of an underlying disease state associated with impairment of performance
status

- New York Heart Association Class IV congestive heart failure

- Limited mental capacity or language skills to the extent simple instructions cannot
be followed or information regarding adverse events cannot be provided

History of non-compliance with prescribed medical care.

- Patients with a history of severe hypersensitivity reaction to Taxotere® or other
drugs formulated with polysorbate 80 must be excluded.